

MR. EZEQUIEL SAGRAY (Orcid ID : 0000-0002-1452-1726)

DR. JONATHAN N JOHNSON (Orcid ID : 0000-0001-7850-0636)

DR. SHAWN C. WEST (Orcid ID : 0000-0002-4369-4394)

Article type : Brief Communication

PROTEIN-LOSING ENTEROPATHY RECURRENCE AFTER PEDIATRIC HEART TRANSPLANTATION: MULTICENTER CASE-SERIES.

Authors:

Sagray, Ezequiel, MD ^a (ORCID # 0000-0002-1452-1726)

Johnson, Jonathan N., MD ^a (ORCID # 0000-0001-7850-0636)

Schumacher, Kurt R., MD ^b (ORCID # 0000-0001-8659-736X)

West, Shawn, MD ^c (ORCID # 0000-0002-4369-4394)

Lowery, Ray E., BA ^b

Simpson, Kathleen, MD ^d (ORCID # 0000-0002-6303-1264)

Author Affiliations:

^a Department of Pediatric and Adolescent Medicine; Division of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota, USA.

^b Division of Pediatric Cardiology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA.

^c University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, Pediatric Cardiology, Pittsburgh, Pennsylvania, USA.

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/PETR.14295](https://doi.org/10.1111/PETR.14295)

This article is protected by copyright. All rights reserved

^d Division of Cardiology, Department of Pediatrics, University of Colorado Denver, Children's Hospital of Colorado, Aurora, Colorado, USA.

Corresponding author:

Kathleen Simpson, MD
Division of Cardiology, Department of Pediatrics
University of Colorado, Children's Hospital of Colorado
13123 East 16th Avenue
Aurora, CO 80045
United States of America
Phone: (720)777-6820
Email: Kathleen.Simpson@childrenscolorado.org

Abbreviations:

PLE: protein-losing enteropathy; HTx: heart transplantation; AVVR: atrioventricular valve regurgitation; PTLT: post-transplant lymphoproliferative disease; CO: cardiac output; CVP: central venous pressure; ANP: atrial natriuretic peptide; BNP: brain natriuretic peptide; HS: heparan sulfate; HSPGs: heparan sulfate proteoglycans; TNF- α : tumor necrosis factor- α ; IFN- γ : interferon- γ ; IL-6: interleukin-6

Conflict of Interest: Authors have no interests to disclose.

Word count: 2079

Funding: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authorship statement:

All authors have substantially contributed by acquiring data for the work, drafting and/or revising the manuscript for intellectual content, and approving final version to be published.

This article is protected by copyright. All rights reserved

Data availability statement:

The data used to support the findings of this study are included within the article.

PROTEIN-LOSING ENTEROPATHY RECURRENCE AFTER PEDIATRIC HEART TRANSPLANTATION: MULTICENTER CASE-SERIES.**Abstract: Background:**

Protein-losing enteropathy (PLE) is a devastating complication of the Fontan circulation. Although orthotopic heart transplantation (HTx) typically results in resolution of PLE symptoms, isolated cases of PLE relapse have been described after HTx.

Methods:

Patients with Fontan-related PLE, who had undergone HTx at participating centers, and experienced relapse of PLE during follow up were retrospectively identified. Available data related to pre- and post-HTx characteristics, and PLE events were collected.

Results:

Eight patients from four different centers were identified. Median time from Fontan procedure to the development of PLE was 8 years, and median age at HTx was 17 years (range 7.7-21). In all patients, PLE resolved at a median time of 1 month after HTx (0.3-5).

PLE recurrences occurred at a median time of 7.5 months after HTx (2-132). Each occurrence was associated with one or more significant clinical events; most commonly cellular- or antibody-mediated rejection, and less commonly graft dysfunction, infection, thrombosis, and post-transplant lymphoproliferative disease. PLE recurrences resolved after the successful treatment of the concomitant event, after a median time of 2 months in 7 cases, while persisted and recurred in one patient in association with atypical mycobacterium infection and subsequent PTLN onset and relapses. Six patients were alive during follow up at a median time of 4 years (1.3-22.5) after HTx.

Conclusions:

This is the largest series of PLE recurrence after HTx. All cases were associated with one or more concomitant and significant clinical events. PLE typically resolved after resolution of the inciting clinical event.

INTRODUCTION

Protein-losing enteropathy (PLE) is characterized by enteric loss of protein including albumin, immunoglobulins, and clotting factors, leading to the clinical findings of peripheral edema, ascites, diarrhea, weight loss, and malabsorption¹. Occurring in 5-12% of cases², it remains as a devastating complication of the Fontan circulation, with significant morbidity and 5-year survival rates of 50-88%^{3,4}.

Even though the mechanisms leading to PLE after Fontan are still not completely understood, hemodynamic conditions, systemic inflammation, lymphatic abnormalities and injury to the intestinal epithelium have been implicated in the pathophysiology of PLE in these patients^{1,5-8}.

Orthotopic heart transplantation (HTx) has shown to be curative therapy for Fontan-related PLE, with Schumacher et al reporting resolution of 98% of PLE cases after a median of 1 month after HTx⁹. Interestingly, the authors described persistence of PLE in 1 of the 43 HTx survivors at long-term follow up, and recurrence of PLE after HTx in another 4 patients⁹. PLE occurrence and recurrence after HTx has been anecdotally reported elsewhere in the literature as well¹⁰⁻¹³. In light of these findings, we sought to examine the characteristics of a multi-institutional cohort patients with PLE recurrence after HTx from major referral centers for Fontan HTx.

METHODS

Patients who developed Fontan-related PLE, had undergone HTx at participating centers, and experienced relapse of PLE during follow up were evaluated. Patients were identified at individual participating centers through retrospective chart review of their respective heart transplant databases. Available clinical, echocardiographic, hemodynamic and/or laboratory pre- and post-HTx data along with data related to PLE relapse was collected.

Definitions:

Active PLE was defined as symptomatic serum hypoalbuminemia, based on assessment of the treating clinician, while resolution of symptoms and normalization of serum albumin levels was defined as *PLE resolution*. *PLE relapse* was defined, in accordance to prior definition used in multicenter study by Schumacher et al⁹, as return of PLE symptoms, with serum hypoalbuminemia and need for treatment after at least 1 month after HTx in a patient who had previously had PLE resolution. *Rejection* was defined as a clinical event prompting augmentation of immunosuppressive therapy, with or without biopsy, in line with the currently accepted definition by the Pediatric Heart Transplant Society. *Infection* included clinical scenarios with presence of signs and symptoms concerning for infection and/or positive microbiological testing requiring initiation of specific directed therapies.

RESULTS

Demographics

Eight patients from four different centers were identified (table 1). Of note, 4 were previously included in the cohort by Schumacher et al⁹ as mentioned above, while the rest have not been reported before. The most common underlying congenital heart disease was hypoplastic left heart syndrome in 4 patients. Two had tricuspid atresia, one double outlet right ventricle and one double inlet left ventricle. In 75% of cases (6/8), the systemic ventricle was the morphologic right ventricle. Median age at the Fontan operation was 2.1 years (range 2-7); 50% (4/8) underwent a lateral tunnel Fontan, one had an initial atriopulmonary Fontan and was then converted to a lateral tunnel-type Fontan, and 3 (37.5%) had an extracardiac Fontan completion. Fontan fenestration was present in 75% (6/8) of patients.

Pre-HTx PLE characteristics

Median time from Fontan procedure to the development of PLE was 8 years (range 0.9-13 years). All patients were treated with albumin infusions and three patients (37.5%) also received IV immunoglobulin as part of their PLE therapy pre-HTx. At time of HTx evaluation, 2 patients presented impaired ventricular function and the remaining 6 presented normal systemic ventricular function by echocardiogram. Data on atrioventricular valve regurgitation (AVVR) was available for 7 patients, being mild or less in 6 patients and moderate to severe in 1 patient.

Pre-HTx hemodynamic data was available in 7 patients. Median cardiac index was 3.2 L/min/m² (range 3.1-4), while median Fontan pressure was 17.0 mmHg (range 12-25). The patient with significantly elevated Fontan pressures of 25 mmHg also presented with impaired ventricular function and moderate to severe AVVR on echocardiography. Systemic ventricular end-diastolic pressure and/or pulmonary capillary wedge pressure widely varied from 7 to 20 mmHg, with a median of 11.0 mmHg.

Post-HTx PLE characteristics

Median age at HTx was 17 years (range 7.7-21), occurring at a median time of 12.2 years (range 3.3-19) after Fontan completion. Half of patients required Extracorporeal Membrane Oxygenation after transplant and one developed acute renal failure requiring dialysis.

In all 8 cases, PLE initially resolved at a median time of 1 month after HTx (range 0.3 to 5 months (data unavailable in 1 case)) after which PLE treatment was discontinued.

PLE relapse

Clinical characteristics of PLE recurrence are depicted in Table 2. PLE recurrence occurred at a median time of 7.5 months after HTx (range 2-132 months). All cases presented with clinical signs of fluid overload, such as peripheral edema and/or ascites, and hypoalbuminemia (albumin level median 2.2 g/dL, range 1.6-2.6, in all 6 patients with data).

In all cases, PLE recurrence was associated with a significant clinical event. The most common was cellular- or antibody-mediated rejection in 5 cases, followed by infection in 3, thrombosis in 2 (superior mesenteric artery and innominate vein), and post-transplant lymphoproliferative disease (PTLD) in 1. There was also clinical, echocardiographic, hemodynamic and/or laboratory evidence of graft dysfunction in 4 cases. In 2 cases there was combination of these events occurring concomitantly with PLE relapse; venous thrombosis and rejection in 1 case, and rejection, influenza A infection and arterial thrombosis in another patient.

In seven patients, there was only one episode of PLE recurrence, which resolved after 0.75, 1, 2, 9 and 10 months after onset (median time of 2 months) (exact time to resolution of PLE relapse was unavailable for 3 patients). One patient (patient #7 in Table 2) presented with several relapses of PLE; first relapse occurred after HTx in association with an atypical mycobacterium

infection, which resolved, and subsequent PLE recurrences developed with PTLD onset and relapses.

Six patients (75%) were alive after a median time of follow up of 4 years (1.3-22.5) after HTx. Among the 2 deaths, one died in a motor vehicle accident, and one suffered a sudden cardiac arrest at home, assumed to be secondary to rejection.

DISCUSSION

To our knowledge, this is the largest case-series on PLE recurrence after HTx. In our cohort we have identified several factors that might have played a role in this phenomenon.

Alterations in cardiac hemodynamics

Low cardiac output (CO) and elevated central venous pressure (CVP) have been previously associated with the development of PLE^{1,3,14}. Although all patients with Fontan physiology have inherently altered CO, relatively higher CO has been reported in PLE Fontan patients compared to non-PLE Fontan patients^{4,15}. In fact, 75% of patients in our cohort were showing normal pre-HTx cardiac index. Unfortunately, data regarding heart failure regimen or use of inotropes at the time of evaluation of CO was limited in detail.

An interesting finding in our cohort was an almost uniform elevation of the pre-HTx CVP, with a median Fontan pressure of 17 mmHg. High Fontan pressure is not always present in PLE patients but appeared to be more consistently present within our cohort of patients who experienced relapse. Even though PLE recurrence occurred after restitution of biventricular circulation, effects of long-standing single ventricle physiology with elevated CVP could have predisposed these patients to PLE recurrence after HTx. Over this background, an acute or subacute hemodynamic insult leading to transiently elevated right heart pressures may trigger the recurrence of PLE after HTx.

These observations are further supported by: 1) the fact that half of our cohort displayed concomitant signs of cardiac allograft dysfunction, and 2) reports of post-HTx PLE recurrence in prior Fontan patients in the setting of severe post-HTx tricuspid valve regurgitation^{10,11}.

Abnormalities of lymphatic system

Both structural and functional abnormalities of the lymphatic system have been described in Fontan patients and could further contribute to the development of post-HTx PLE recurrence. Structural derangements include dilation of the thoracic duct, lymphangiectasia, lymphatic

collateralization and the presence of hepatoduodenal lymphatic channels^{7,8,16}. These hepatoduodenal lymphatic connections may be an anatomical variant with otherwise no clinical significance in patients without elevated CVP, but they could become clinically evident in Fontan patients with persistently elevated venous pressure, and subsequent lymphatic congestion⁸. Conversely, prolonged single physiology may be a nidus for development of lymphatic system abnormalities over time, which could also persist after HTx

Functional lymphatic abnormalities have been described in response to neurohumoral stimulation, and may further contribute to the development of PLE after HTx. Both atrial (ANP) and brain (BNP) natriuretic peptides experimentally alter the mesenteric lymphatic collection, by affecting the lymphatics' spontaneous contractions and increasing the permeability to albumin and fluid¹⁷. ANP and BNP are secreted in response to myocardial stress, in the context of volume and/or pressure overload¹⁸. BNP also increases in response to cardiac allograft rejection, mediated by inflammatory cytokines¹⁹. These findings might explain how elevation of biomarkers could not only contribute to PLE relapse during an episode of rejection and/or hemodynamic derangement, but also how adequate treatment of the hemodynamic insult or rejection-mediated inflammatory response could lead to resolution of the PLE relapse.

Inflammation

Recent studies suggest that PLE development in Fontan patients is likely related to both intestinal and systemic pro-inflammatory states^{20,21}. At the intestinal level, the loss of heparan sulfate (HS) and HS proteoglycans (HSPGs) from the basolateral membrane of the enterocytes, which could occur in pro-inflammatory states due to higher epithelial barrier turnover²², has been described during PLE episodes²³, with reappearance of HS after resolution of PLE²⁴. In relation to this, based on previous experimental models of PLE, Bode et al suggested that certain genetic mutations, affecting the expression of genes involved in the biosynthesis, expression or metabolism of HSPGs, could predispose Fontan patients to develop PLE²⁵. Furthermore, this altered gene expression could be provoked by venous hypertension²⁵.

At a systemic level, chronic congestive heart failure and low cardiac output result in the activation of a systemic inflammatory response^{15,26}, in which pro-inflammatory cytokines, such as tumor necrosis factor- α (TNF- α), interferon- γ (IFN- γ), C-reactive protein and interleukin-6 (IL-6) can be increased^{26,27}. Using a tissue culture model, Bode et al⁶ demonstrated that

disruption of the intestinal epithelial barrier and protein leakage were induced synergistically by an elevated venous pressure, TNF- α (potentiated by IFN- γ) and loss of HS. In our cohort, PLE recurrence mostly occurred in association with infection, cardiac allograft rejection, and/or PTLD. In this manner, rejection and PTLD have been in fact associated with a pro-inflammatory state with cytokine release, mostly IL-6²⁸⁻³⁰. We speculate that an inflammatory stimulus could have triggered the PLE recurrence in our cohort, most likely on the background of structural and/or functional lymphatic abnormalities and chronic, acute or acute-on-chronic altered hemodynamics. These observations are further supported by the fact that episodes of PLE recurrence in our cohort resolved in all patients after resolution of the inciting clinical event, and even continued to recur in one patient with subsequent PTLD relapses. This could indicate important prognostic features in the case of PLE recurrence after HTx.

Limitations

The authors acknowledge that a limitation of the study is the presence of missing data, both pre- and post-HTx, more importantly regarding time to resolution of PLE relapse and levels of albumin during PLE relapses. These cases involved patients who underwent HTx and developed recurrence of PLE at least more than 10-15 years before the conduction of the present study. As available data was collected by authors at each participating institution's database, missing data was related mostly to transfer of care of patient and/or provider moving to a different institution. In this manner, the authors clarify that these patients were included due to medical records specifically documented a clear clinical scenario of PLE symptoms and hypoalbuminemia, even though serum albumin levels could not be recovered.

CONCLUSIONS

Although the pre- and post-HTx histories and presentations were diverse within our study cohort, we hypothesize that PLE recurrence could have occurred as a result of several interrelated factors, many of which likely contributed to PLE pathogenesis prior to transplant. Long-standing Fontan circulation, with primarily elevated CVP, was present pre-HTx, and secondary lymphatic structural abnormalities could have developed and even persisted after HTx. An index clinical event occurred in all cases concomitantly with PLE recurrence which most likely enhanced a systemic pro-inflammatory state with release of cytokines, directly or indirectly leading to

lymphatic functional abnormalities, disruption of the intestinal epithelial barrier, and protein leakage. The fact that PLE resolved after resolution of the inciting clinical events not only supports our hypothesis, but also provides prognostic implications to providers encountering PLE recurrence after HTx.

REFERENCES

1. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the fontan operation. *J Am Coll Cardiol*. 2014;64(1):54-62. doi:10.1016/j.jacc.2014.04.025
2. Rychik J, Atz AM, Celermajer DS, et al. Evaluation and Management of the Child and Adult with Fontan Circulation: A Scientific Statement from the American Heart Association. *Circulation*. 2019;140(6):E234-E284. doi:10.1161/CIR.0000000000000696
3. Johnson JN, Driscoll DJ, O'Leary PW. Protein-losing enteropathy and the Fontan operation. *Nutr Clin Pract*. 2012;27(3):375-384. doi:10.1177/0884533612444532
4. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the fontan operation: An international multicenter study. *J Thorac Cardiovasc Surg*. 1998;115(5):1063-1073. doi:10.1016/S0022-5223(98)70406-4
5. Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNF α) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. *J Cell Sci*. 1999;112(1):137-146.
6. Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. *J Biol Chem*. 2006;281(12):7809-7815. doi:10.1074/jbc.M510722200
7. Dori Y, Keller MS, Fogel MA, et al. MRI of lymphatic abnormalities after functional single-ventricle palliation surgery. *Am J Roentgenol*. 2014;203(2):426-431. doi:10.2214/AJR.13.11797
8. Itkin M, Piccoli DA, Nadolski G, et al. Protein-Losing Enteropathy in Patients With Congenital Heart Disease. *J Am Coll Cardiol*. 2017;69(24):2929-2937. doi:10.1016/j.jacc.2017.04.023
9. Schumacher KR, Yu S, Butts R, et al. Fontan-associated protein-losing enteropathy and post-heart transplant outcomes: A multicenter study. *J Hear Lung Transplant*. 2019;38(1):17-25. doi:10.1016/j.healun.2018.09.024

10. Aggarwal S, Delius RE, Walters HL, L'Ecuyer TJ. Recurrent Protein-Losing Enteropathy and Tricuspid Valve Insufficiency in a Transplanted Heart: A Causal Relationship? *Congenit Heart Dis*. May-Jun 2012;7(3):E10-3. doi:10.1111/j.1747-0803.2011.00557.x.
11. Carlo WF, Bennett Pearce F, Kirklin JK. Retransplantation as a successful therapy for post-transplant protein-losing enteropathy. *J Hear Lung Transplant*. 2013;32(4):472-473. doi:10.1016/j.healun.2012.12.015
12. Bare I, Akhtar J, Orvold J, Haddad H, Zhai A. Protein Losing Enteropathy in a Post-Cardiac Transplant Adult: A Case Report. *J Card Fail*. 2018;24(8):S83. doi:10.1016/j.cardfail.2018.07.333
13. Worme MD, Scolari F, Kozuszko S, Alonso-Gonzalez R. Protein Losing Enteropathy - Clinical Resolution Post Heart Transplant and Recurrence after CMV Enteritis. *J Hear Lung Transplant*. 2021;40(4):S483. doi:10.1016/j.healun.2021.01.1988
14. Al Balushi A, Mackie AS. Protein-Losing Enteropathy Following Fontan Palliation. *Can J Cardiol*. 2019;35(12):1857-1860. doi:10.1016/j.cjca.2019.07.625
15. Rychik J. Protein-Losing enteropathy after fontan operation. *Congenit Heart Dis*. 2007;2(5):288-300. doi:10.1111/j.1747-0803.2007.00116.x
16. Mohanakumar S, Telinius N, Kelly B, et al. Morphology and Function of the Lymphatic Vasculature in Patients With a Fontan Circulation. *Circ Cardiovasc Imaging*. 2019;12(4):e008074. doi:10.1161/CIRCIMAGING.118.008074
17. Scallan JP, Davis MJ, Huxley VH. Permeability and contractile responses of collecting lymphatic vessels elicited by atrial and brain natriuretic peptides. *J Physiol*. 2013;591(20):5071-5081. doi:10.1113/jphysiol.2013.260042
18. Talha S, Charloux A, Piquard F, Geny B. Brain natriuretic peptide and right heart dysfunction after heart transplantation. *Clin Transplant*. 2017;31(6). doi:10.1111/ctr.12969
19. Ma KK, Ogawa T, De Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. *J Mol Cell Cardiol*. 2004;36(4):505-513. doi:10.1016/j.yjmcc.2004.01.001
20. Rodríguez de Santiago E, Téllez L, Garrido-Lestache Rodríguez-Monte E, et al. Fontan protein-losing enteropathy is associated with advanced liver disease and a

- proinflammatory intestinal and systemic state. *Liver Int.* 2020;40(3):638-645.
doi:10.1111/liv.14375
21. Manning LN, Schumacher KR, Friedland-Little JM, et al. Impact of Protein-Losing Enteropathy on Inflammatory Biomarkers and Vascular Dysfunction in Fontan Circulation. *Am J Cardiol.* 2021;155:128-134. doi:10.1016/j.amjcard.2021.06.022
 22. Bode L, Eklund EA, Murch S, Freeze HH. Heparan sulfate depletion amplifies TNF- α -induced protein leakage in an in vitro model of protein-losing enteropathy. *Am J Physiol - Gastrointest Liver Physiol.* 2005;288(5 51-5):1015-1023. doi:10.1152/ajpgi.00461.2004
 23. Murch SH, Salvestrini C, Myrdal U, et al. *P0584 Focal Loss of Duodenal Enterocyte Heparan Sulphate Proteoglycans May Contribute To Protein-Losing Enteropathy After Fontan Surgery.* Vol 39.; 2004. doi:10.1097/00005176-200406001-00708
 24. Westphal V, Murch S, Kim S, et al. Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation. *Am J Pathol.* 2000;157(6):1917-1925. doi:10.1016/S0002-9440(10)64830-4
 25. Bode L, Freeze HH. Applied glycoproteomics-approaches to study genetic-environmental collisions causing protein-losing enteropathy. *Biochim Biophys Acta - Gen Subj.* 2006;1760(4):547-559. doi:10.1016/j.bbagen.2005.11.004
 26. Ostrow AM, Freeze H, Rychik J. Protein-Losing Enteropathy After Fontan Operation: Investigations Into Possible Pathophysiologic Mechanisms. *Ann Thorac Surg.* 2006;82(2):695-700. doi:10.1016/j.athoracsur.2006.02.048
 27. Shimizu T, Nagata S, Fujii T, et al. Enhanced production of interferon-gamma as a possible cause of protein-losing enteropathy after modified Fontan operation. *J Pediatr Gastroenterol Nutr.* 2003;37(4):504-507. doi:10.1097/00005176-200310000-00019
 28. Petrara MR, Giunco S, Serraino D, Dolcetti R, De Rossi A. Post-transplant lymphoproliferative disorders: From epidemiology to pathogenesis-driven treatment. *Cancer Lett.* 2015;369(1):37-44. doi:10.1016/j.canlet.2015.08.007
 29. Przybyłek B, Boethig D, Neumann A, et al. Novel Cytokine Score and Cardiac Allograft Vasculopathy. *Am J Cardiol.* 2019;123(7):1114-1119. doi:10.1016/j.amjcard.2018.12.034
 30. Jordan SC, Ammerman N, Choi J, et al. Interleukin-6: An important mediator of allograft injury. *Transplantation.* 2020:2497-2506. doi:10.1097/TP.0000000000003249

LEGENDS**Table 1:**

Data left blank is unavailable.

HLHS: hypoplastic left heart syndrome; DORV: double outlet right ventricle; TA/PS: tricuspid atresia/pulmonary stenosis; TA/TGA: tricuspid atresia/transposition of the great arteries; LT: lateral tunnel; EC: extracardiac; AP: atriopulmonar; HTx: orthotopic heart transplantation; AVVR: atrioventricular valve regurgitation; CI: cardiac index; EDP/PCWP: end-diastolic pressure/pulmonary capillary wedge pressure.

* L/min/m²

Table 2:

Data left blank is unavailable.

AMR: antibody-mediated rejection; CMR: cellular-mediated rejection; EDP: end-diastolic pressure; BNP: brain natriuretic peptide; TR: tricuspid regurgitation; PTLN: posttransplant lymphoproliferative disease; SMA: superior mesenteric artery; MVA: motor vehicle accident; ARF: acute renal failure; SVC: superior vena cava, ECMO: extracorporeal membrane oxygenation.

Table 1. Pre-HTx characteristics.

Patient	CHD	Morphologic Ventricle	Age at Fontan (yrs)	Fontan Type	Fenestration	Time from Fontan to PLE (yrs)	Time from Fontan to HTx (year)	Pre-HTx AVVR	Pre-HTx Ventricular function	Pre-HTx Fontan pressure	Pre-HTx CI*	Pre-HTx EDP/PCWP	Age at HTx (yrs)
1	HLHS	Right	2.1	LT	No	0.9	13.4	trace	Preserved	17	4	11	15.4
2	HLHS	Right	2	LT	Yes	11	19	mild	Preserved	12	3.2	7	21
3	HLHS	Right	2	LT	Yes	13	4	mod-sev	Impaired	25	3.7	20	17
4	DORV	Right	2	EC	Yes	8	15	mild	Preserved	12		11	17
5	HLHS	Right	3.5	EC	Yes	1.5	3.3	mild	Impaired	15	3.1	9	7.7
6	TA/PS	Left	7	AP, then LT	No	10	10.6		Preserved				17.6
7	TA/TGA	Left	2	LT	Yes		16	mild	Preserved	17	3.2	13	18.8
8	DORV	Right	3	EC	Yes	3	11	none	Preserved	20	3.2	16	14
Median			2.1			8.0	12.2			17	3.2	11.0	17.0

Data left blank is unavailable.

HLHS: hypoplastic left heart syndrome; DORV: double outlet right ventricle; TA/PS: tricuspid atresia/pulmonary stenosis; TA/TGA: tricuspid atresia/transposition of the great arteries; LT: lateral tunnel; EC: extracardiac; AP: atriopulmonary; HTx: orthotopic heart transplantation; AVVR: atrioventricular valve regurgitation; CI: cardiac index; EDP/PCWP: end-diastolic pressure/pulmonary capillary wedge pressure

* L/min/m²

Table 2. Post-HTx and PLE relapse characteristics.

Patient	Age at HTx (yrs)	Months to PLE resolution	HTx to first PLE recurrence (months)	Concurrent clinical issue w/PLE	PLE symptoms	Albumin level	PLE recurrence resolution	Time to resolution (months)	Alive at follow-up?	Last follow-up (years since HT)	Notes
1	15.4	1	4.4	Allograft dysfunction, AMR	low albumin	2.6	Y		N	4.8	<ul style="list-style-type: none"> Recurrent episodes of rejection. Died from sudden cardiac arrest at home (presumed rejection)
2	21	0.5	8	Necrotizing fasciitis, sepsis	edema, ascites, low albumin	2.1	Y	2	N	3	<ul style="list-style-type: none"> Died in MVA
3	17	0.3	10	CMR	low albumin, edema	2.2	Y	0.8	Y	4	<ul style="list-style-type: none"> HTx complicated by graft dysfunction requiring ECMO, and dialysis
4	17	4	6	Elevated RVEDp (early after AMR that was improving on biopsy)	low albumin, ascites	2.6	Y	10	Y	1.3	<ul style="list-style-type: none"> HTx complicated by coagulopathy and bleeding, ARF and dialysis, SVC syndrome
5	7.7	2	26	Venous thrombus, elevated EDP and BNP levels; treated for rejection	low albumin, edema, ascites	1.6	Y	9	Y	3	

6	17.6		132	Allograft dysfunction and severe TR	low albumin, edema		Y		Y	22.5	<ul style="list-style-type: none"> HTx complicated by graft dysfunction requiring ECMO PTLD
7	18.8	5	7	Atypical mycobacterium infection, then PTLD continues with symptoms as PTLD recurs	low albumin, diarrhea, ascites	1.7	N		Y	4	<ul style="list-style-type: none"> HTx complicated by graft dysfunction requiring ECMO
8	14	1	2	Influenza A infection Rejection SMA thrombosis	low albumin, ascites		Y	1	Y	8	<ul style="list-style-type: none"> HTx complicated by graft dysfunction requiring ECMO

Data left blank is unavailable.

AMR: antibody-mediated rejection; CMR: cellular-mediated rejection; EDP: end-diastolic pressure; BNP: brain natriuretic peptide; TR: tricuspid regurgitation; PTLD; posttransplant lymphoproliferative disease; SMA: superior mesenteric artery; MVA: motor vehicle accident; ARF: acute renal failure; SVC: superior vena cava, ECMO: extracorporeal membrane oxygenation